— First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to MASH — — Phase 3 SYNCHRONY Real-World and Histology studies on track to report results for their respective primary endpoints in 2026 and the first half of 2027 — — Phase 2b SYMMETRY study week 96 results expected to readout in February 2025 — SOUTH SAN FRANCISCO, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage ...

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced an upcoming oral presentation and two late-breaking poster presentations at the 75th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 taking place from November 15-19, 2024, in San Diego. The presentations ...

Group 1 - Moore Law, PLLC is investigating potential claims against Akero Therapeutics, Inc. regarding misrepresentations about the patient population in the SYMMETRY study [1] - The investigation highlights that approximately 20% of the tested patients had not confirmed NASH as the cause of their cirrhosis, which is critical for data integrity [1] - Akero's stock price fell by $30.39 per share, or 62.61%, closing at $18.15 per share following disappointing interim data from the Phase 2b SYMMETRY trial [2] Group 2 - In the SYMMETRY trial, only 22% (28mg) and 24% (50mg) of patients on EFX showed at least one stage improvement in fibrosis, with no worsening of NASH, but these results were not statistically significant [2] - The trial faced issues with patient discontinuation, with 12 patients, including 11 from EFX groups, dropping out due to drug-related adverse events [2]

I covered Akero Therapeutics (NASDAQ: AKRO ) in May last year when we were awaiting data from the phase 2b SYMMETRY study. Since then, two events negative for the stock have taken place. One, poor SYMMETRY data, and two, Madrigal’s (About the TPT serviceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material.  ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38944 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 81-5266573 (State or othe ...

Exhibit 99.1 Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update -- Initiated Phase 3 SYNCHRONY Outcomes Trial of Lead Candidate Efruxifermin (EFX) in Patients with Compensated Cirrhosis (F4) Due to MASH -- Presented Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024 -- -- Leadership Team Expanded with Addition of Scott Ganglof as Chief Technical Of icer -- SOUTH SAN FRANCISCO, Calif. August 9, 2024 /GLOBE NEWSWIRE/ – Akero Therapeutics, Inc ...

-- Initiated Phase 3 SYNCHRONY Outcomes Trial of Lead Candidate Efruxifermin (EFX) in Patients with Compensated Cirrhosis (F4) Due to MASH -- Presented Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024 -- -- Leadership Team Expanded with Addition of Scott Gangloff as Chief Technical Officer -- SOUTH SAN FRANCISCO, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serio ...

NEW YORK, July 17, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Akero Therapeutics, Inc. (NASDAQ: AKRO) on behalf of the company's shareholders. The investigation seeks to determine whether Akero's directors breached their fiduciary duties in connection with recent corporate actions.If you are a shareholder of Akero Therapeutics, Inc. and are interested in obtaining additional information regarding your rights and options, free of charge, please visit us at: https://pjlfir ...

Akero Therapeutics, Inc. (AKRO) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power ...

LOS ANGELES, June 25, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ: AKRO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 13, 2022 and October 9, 2023, inclusive (the "Class Per ...